(EMAILWIRE.COM, November 23, 2010 ) New York, NY-AMCOL International Corporation (NYSE:ACO) fell 3.45% to $27.81 after the company's Chief Executive Lawrence Washow said it is planning to retire at the end of the year, and the specialty-minerals company selected Chief Operating Officer Ryan McKendrick as his successor.
AMCOL International Corporation operates in five segments: minerals and materials, environmental, oilfield services, transportation and corporate.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) slid 5% to $4.39 on very unusual volume after it reported improved results from a Phase II clinical trial of rindopepimut, a vaccine that targets the most common type of brain tumors.
The immunotherapy company's data showed 66% of patients were progression-free eight and a half months from diagnosis or five and a half months from the start of vaccination.
Celldex Therapeutics, Inc. (Celldex) is a biopharmaceutical company, which applies its Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases.
Cyberonics, Inc. (NASDAQ:CYBX) soared 9.25% to $29.71 and made a new 52-week high of $30.26 after the company said it earned $24.94 million or $0.88 a share on revenue of $47.46 million in its fiscal quarter, compared to year ago profit of $50.14 million or $1.73 per share on revenue of $40.72 millio $40.72 million.
Analysts' were expecting the company to report 25 cents a share on revenue of $46.13 million.
Cyberonics, Inc. (Cyberonics) is a neuromodulation company engaged in the design, development, sales and marketing of implantable medical devices that provide a therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression.
Epic Stock Picks provides free Penny stock newsletters on various stocks including penny stocks of the day. EpicStockPicks.com team of experts delve into the micro and small-cap world of stocks, including big board pennies, searching for equities that are undervalued, yet show great promise of future growth.
EpicStockPicks.com will not be responsible for or accept any liability for any losses arising from an investor's reliance on or use of information obtained from Epic Stock Picks' website or emails. http://www.EpicStockPicks.com does its best to verify, but does not guarantee the topicality, correctness, completeness and quality of information and statements presented on its website and emails. EpicStockPicks.com s company officers are not registered investment advisors and do not recommend to buy, hold, or sell any securities. EpicStockPicks.com simply provides information and ideas to investors as they gather investment information. The onus is on viewers to complete their own due diligence. EpicStockPicks.com viewers should always make their own financial decisions.